Scarica l'app Stockscreener
1.0218
3.60%
-0.0382
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.06
Aprire:
$1.05
Volume 24 ore:
226.00K
Relative Volume:
0.62
Capitalizzazione di mercato:
$12.51M
Reddito:
$10.72M
Utile/perdita netta:
$-39.71M
Rapporto P/E:
-0.0657
EPS:
-15.5542
Flusso di cassa netto:
$-32.21M
1 W Prestazione:
+10.41%
1M Prestazione:
+2.68%
6M Prestazione:
-71.77%
1 anno Prestazione:
-89.55%
Intervallo 1D:
$1.02
$1.10
Intervallo di 1 settimana:
$0.9302
$1.10
Portata 52W:
$0.8435
$21.60
Jaguar Health Inc Stock (JAGX) Company Profile
Nome
Jaguar Health Inc
Settore
Industria
Telefono
415-371-8300
Indirizzo
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Confronta JAGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.0218 | 12.51M | 10.72M | -39.71M | -32.21M | -6.9342 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.68 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.83 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
626.84 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.21 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.54 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - MSN
FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer - MSN
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Barchart
Jaguar Health's Magdalena JV Imports 6kg of Coca Leaf for Novel Mental Health Drug Development - StockTitan
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Corsicana Daily Sun
Jaguar Health Launches Phase 2 Trial for Rare Pediatric Disease Treatment with Orphan Drug Status - StockTitan
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera - Eagle-Tribune
Jaguar Health Secures FDA Orphan Drug Status for Groundbreaking Cholera Treatment - StockTitan
Jaguar Health stock plunges to 52-week low of $0.87 By Investing.com - Investing.com Canada
Jaguar Health stock plunges to 52-week low of $0.87 - Investing.com
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Quantisnow
Jaguar Health Advances 5 Clinical Trials for Rare Disease Drug Crofelemer, Unveils Development Roadmap - StockTitan
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Yahoo Finance
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - AccessWire
Jaguar Health's Phase 3 Trial Shows Breakthrough Results for Cancer Therapy Diarrhea Treatment - StockTitan
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Corsicana Daily Sun
Jaguar Health to Present Promising Breast Cancer Treatment Data at Major Symposium - StockTitan
Jaguar Health Launches Major Clinical Trial for Orphan Drug Crofelemer in Short Bowel Syndrome - StockTitan
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - Yahoo Finance
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - Corsicana Daily Sun
Botanical and Plant-Derived Drugs Market to grow by USD 20.93 Billion (2024-2028), driven by government initiatives, with AI powering market evolutionTechnavio - The Malaysian Reserve
Jaguar Health Targets 6M Annual Cases With Novel Dog Diarrhea Drug NP300 - StockTitan
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference - AccessWire
Jaguar Health CEO to Present at NobleCon20 and Emerging Growth Conference | JAGX Stock News - StockTitan
Jaguar Health seeking partner to develop, commercialize NP300 - TipRanks
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - WSIL TV
Jaguar Health Seeks Partner for Novel Dog Diarrhea Drug Targeting 6M Annual Cases | JAGX Stock News - StockTitan
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - AccessWire
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Earnings call: Jaguar Health reports revenue growth in Q3 2024 By Investing.com - Investing.com Nigeria
Earnings call: Jaguar Health reports revenue growth in Q3 2024 - Investing.com
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Jaguar Health extends agreement with financial managers - Investing.com India
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Jaguar Health Sees Revenue Growth with New Product Launches - TipRanks
Jaguar Health extends agreement with financial managers By Investing.com - Investing.com UK
Jaguar Health reports Q3 EPS ($1.05) vs. ($22.50) last year - TipRanks
Jaguar Health Reports Third Quarter 2024 Financial Results - Yahoo Finance
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Bluefield Daily Telegraph
Jaguar Health (JAGX) Sets Q3 2024 Earnings Call: Key Financial Updates Coming - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27% - Simply Wall St
Jaguar Health stock hits 52-week low at $0.93 amid challenges By Investing.com - Investing.com South Africa
Jaguar Health stock hits 52-week low at $0.93 amid challenges - Investing.com India
Jaguar Health Inc Azioni (JAGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):